Literature DB >> 16399527

Prognostic value of the QTc interval after cardiac transplantation.

Bojan Vrtovec1, Rajko Radovancevic, Cynthia D Thomas, Aria P Yazdabakhsh, Frank W Smart, Branislav Radovancevic.   

Abstract

BACKGROUND: Although QTc interval prolongation is considered a risk factor for adverse outcome in the non-transplant population, its predictive value in heart transplant recipients has not been studied yet. This study was conducted to determine whether prolonged QTc interval is a useful predictor of outcome in heart transplant recipients.
METHODS: QTc intervals were measured in 587 adult patients who underwent heart transplantation between May 1982 and January 2002. QT interval duration was determined by averaging 3 consecutive beats in all 12 leads of the standard electrocardiogram (ECG) and corrected with the Bazett formula. Baseline ECGs were obtained within 7 days after transplantation; follow-up ECGs were recorded annually at the time of routine angiography. Patients were followed over 85 +/- 65 months (range, 3 months-17 years).
RESULTS: During follow-up, 241 patients died. The mean QTc interval duration in these patients was comparable with that in the remaining cohort (432 +/- 26 msec vs 423 +/- 25 msec, p = 0.07). However, patients with a relative increase in QTc duration of >or=10% between the first and second post-transplantation year (DeltaQTc >or= 10%) had a 6.86-times higher risk of dying compared with patients with DeltaQTc < 10% (p = 0.0005). Furthermore, DeltaQTc >or= 10% was the only independent predictor of long-term mortality on multivariate analysis (p = 0.0008).
CONCLUSIONS: A relative increase in QTc interval duration of >or=10% between the first and second post-transplantation year is a strong, independent predictor of mortality in heart transplant recipients.

Entities:  

Mesh:

Year:  2005        PMID: 16399527     DOI: 10.1016/j.healun.2005.05.004

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

1.  Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia.

Authors:  R Zhang; A Haverich; M Strüber; A Simon; M Pichlmaier; Christoph Bara
Journal:  Clin Res Cardiol       Date:  2008-07-21       Impact factor: 5.460

2.  Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study.

Authors:  Ruoyu Zhang; Dmitry Bobylev; Penelope Stiefel; Axel Haverich; Christoph Bara
Journal:  Clin Res Cardiol       Date:  2012-03-04       Impact factor: 5.460

3.  Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

Authors:  Luigi X Cubeddu
Journal:  Curr Cardiol Rev       Date:  2009-08

4.  Late sinus and atrial tachycardia after pediatric heart transplantation might predict poor outcome.

Authors:  R Peter Vande Kappelle; Katheryn Gambetta; Barbara J Deal; Carl L Backer; Christine L Sullivan; Elfriede Pahl
Journal:  Pediatr Cardiol       Date:  2010-02-18       Impact factor: 1.655

5.  Remote noninvasive allograft rejection monitoring for heart transplant recipients: study protocol for the novel evaluation with home electrocardiogram and remote transmission (NEW HEART) study.

Authors:  Lynn V Doering; Kathleen Hickey; David Pickham; Belinda Chen; Barbara J Drew
Journal:  BMC Cardiovasc Disord       Date:  2012-03-02       Impact factor: 2.298

Review 6.  Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.

Authors:  Luigi X Cubeddu
Journal:  Curr Cardiol Rev       Date:  2016

7.  Arrhythmias after heart transplantation: mechanisms and management.

Authors:  Anees Thajudeen; Eric C Stecker; Michael Shehata; Jignesh Patel; Xunzhang Wang; John H McAnulty; Jon Kobashigawa; Sumeet S Chugh
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

8.  Long QT interval as a marker in acute graft rejection in heart transplant: A case report.

Authors:  Cristhian F Ramirez-Ramos; Diego A Echeverri-Marin; Clara I Saldarriaga-Giraldo; Juan D Ramirez-Barrera; Juan F Agudelo-Uribe; Ricardo Fernandez-Ruiz; Alvaro Quintero
Journal:  Arch Cardiol Mex       Date:  2022-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.